As part of SHL’s efforts to reach out to the biopharmaceutical industry in the Asia Pacific region and to better understand their needs, SHL will speak exhibit at the PDA’s upcoming Prefilled Syringe Seminar in Tokyo, Japan.
Taoyuan, Taiwan, May 03, 2012 -- Auto injectors have proven to be one of the most convenient and safe methods for patients to self-administer their injections. This trend has become even more noticeable as the number of combination products coming to market continues to increase and biopharmaceutical companies seek to diversify the range of drug delivery options for their products. To support this growth, auto injectors must continue to evolve in both design and functionality.
For several years, a range of auto injectors have been available in the European and North American markets, but more recently countries in the Asia Pacific region are starting to see such devices launched in their markets. Biopharmaceutical companies based in this region are now beginning to work with experienced drug delivery device companies to help design devices that are ideally suited to the needs of their customers. However, selecting the right device partner is crucial when starting up any auto injector program, especially when the project may involve collaborations at a global level. Take the Japanese biopharmaceutical industry as an example, which is very RD oriented and has quite strict regulatory guidelines, it's essential that the device manufacturer is knowledgeable and experienced enough to tailor device programs to meet the requirements of that market.
As part of SHL's efforts to reach out to the biopharmaceutical industry in the Asia Pacific region and to better understand their needs, SHL Marketing Director Steven Kaufman will be presenting on the topic 'Auto injectors: Supporting the Biotech Revolution' at the upcoming 'Prefilled Syringe Seminar' held by the Parental Drug Association Japan (PDA Japan) from May 22nd-23rd.
SHL will be showcasing key auto injectors such as MollyTM (a simple 2-step shield activated auto injector) DAITM (one of the most successful auto injectors launched) and SDI-MIX NITTM (a dual-chamber auto injector that utilizes the latest in needle isolation technology) while exhibiting at the seminar. Handling videos and live demonstrations will also be available for attendees.
SHL is the world's largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. SHL has over 1,800 staff globally, with primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in RD has enhanced the company's broad pipeline of "next generation" drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Contact : Website: www.shl-group.com, Email: email@example.com, SHL Media Contact, Steven R. Kaufman, Marketing Director, +886 3-217-0303, firstname.lastname@example.org